National DNA Day Q&A with Hereditas' Editor-in-Chief
Published in Cancer, Protocols & Methods, and Genetics & Genomics
Explore the Research
BioMed Central
Editorial: Celebration of DNA Day - Hereditas
Hereditas volume 161, Article number: 16 (2024) Cite this article
Dr. Ramin Massoumi earned his PhD at Lund University, Sweden, where he investigated the role of inflammation in colon cancer development, and then pursued postdoctoral research at the Max Planck Institute for Biochemistry in Germany, focusing on genetic changes and signalling involved in various types of skin cancer. His research group now centres on cancer biology and the development of novel anticancer drugs. Dr. Massoumi has received prestigious awards, including grants from the European Research Council and Novo Nordisk, and is the founder of IVRS. He also serves on multiple editorial boards and has been Editor-in-Chief of Hereditas since 2024.
- Please tell us about yourself, and your role in the journal Hereditas. How does your research relate to the celebration of National DNA Day?
My name is Ramin Massoumi, Prof. in Molecular Oncology and the Editor-in-Chief of Hereditas, one of the pioneering journals in genetics. My research focuses on uncovering how genetic changes in DNA contribute to the development of diseases such as cancer. In our research, we use animal models to simulate DNA alterations, which helps us understand how cancer develops and identify new therapeutic targets. This work is directly tied to DNA Day, as it underscores the profound impact that genetic research has on improving human health and fostering innovation in medical research.
- What does DNA Day celebrate, and why is it so important?
In my opinion, DNA Day celebrates two monumental milestones: the discovery of the DNA double helix and the completion of the Human Genome Project. These achievements have revolutionised our understanding of life and disease. For researchers, DNA Day serves as a powerful reminder of the strides made in deciphering how genetic mutations lead to diseases such as cancer, and it inspires continued efforts to translate these insights into effective therapies.
- What are some of the most exciting recent developments in DNA research?
Recent developments in DNA research are truly groundbreaking. Two particularly exciting advances include CRISPR and gene editing, which allows for precise modifications of genes, opening promising avenues for treating genetic diseases, including cancer. Liquid biopsy is another recent development that allows for minimally invasive tests to detect cancer by analysing DNA fragments released by tumours in the bloodstream, enabling early diagnosis and improved monitoring of disease progression.
- What role does DNA research play in current medical advancements?
DNA research is central to modern medicine. It drives the development of precision medicine and allows treatments to be tailored to an individual’s genetic profile. In oncology, genetic screening facilitates the early detection of cancers before symptoms arise and understanding the genetic mutations behind tumour development leads to the creation of targeted therapies. Moreover, advancements in gene therapy can correct inherited oncology disorders by addressing their genetic root causes.
- How does DNA Day help the public understand genetics and molecular biology?
DNA Day bridges the gap between complex scientific research and everyday understanding. It provides an opportunity to explain how our DNA not only defines who we are but also plays a critical role in the development of diseases such as cancer. By explaining concepts such as gene mutations and personalised medicine, DNA Day empowers the public to make informed health decisions and builds trust in the advancements of genetic science.
- What are some of the key ethical considerations in DNA research?
There are many key ethical considerations in DNA research. Protecting genetic privacy, ensuring informed consent for genetic testing, and providing equitable access to emerging genetic therapies are a few examples. As we develop transformative technologies and gene editing, it is crucial to address the implications of germline modifications to ensure that the benefits of these innovations are shared fairly and responsibly.
- How can Early Careers Researchers and students get involved in DNA Day activities?
Young researchers and students have a variety of ways to engage with DNA Day. Participating in school or university events, hosting public seminars, or creating accessible content on social media that explains genetic concepts in simple terms are a few examples. Involvement in science projects or visiting research labs can also spark inspiration and open doors to exciting career opportunities in genetics and biomedical research.
- How do you see the future of DNA research unfolding in the next 10-20 years?
Over the next two decades, I envision DNA research transforming healthcare in several ways. Personalised medicine will become the standard of care, tailoring treatments to everyone’s genetic profile. Gene-editing technologies like CRISPR are expected to expand from addressing rare diseases to tackling common conditions such as cancer, heart disease, and neurodegenerative disorders. Additionally, the integration of DNA data into everyday healthcare with the help of artificial intelligence will revolutionise diagnostics and treatment, making genetic insights an integral part of medical decision-making.
- What message would you want to convey to people about the importance of DNA and genetics in their everyday lives?
Genetics is not just the realm of scientists; it is an essential component of everyday healthcare. From routine cancer screening to personalised treatment plans, our understanding of DNA directly influences how we prevent and treat disease. The future of medicine is inherently genetic, and by deepening our knowledge of genetics, we can improve health outcomes and enhance the quality of life for everyone.
- Finally, what do you want to say to all our editors, board members, reviewers, researchers, authors, publishers and the general public on DNA Day?
Every cell in your body holds a unique genetic story, and DNA Day is a celebration of the remarkable science that allows us to read and understand that story. It reminds us that every genetic detail contributes to the broader narrative of human health and disease, inspiring us to appreciate and harness the power of our genetic heritage for a better future.
Poster image: © [M] ktsdesign / Stock.adobe.com
Interview created, formatted, and edited by India Sapsed-Foster, Associate Publisher, with special thanks to Ramin Massoumi for his contributions and valuable insights into the role of DNA in cancer research.
Follow the Topic
-
Hereditas
Hereditas publishes original cutting-edge research and reviews. The journal welcomes research from across all areas of human, plant, animal and microbial genetics and epigenetics. Topics of interest also include cancer genetics, cancer biology, non-coding RNA, Data Mining, and Genome Technology.
Related Collections
With collections, you can get published faster and increase your visibility.
Deep learning the genome
The field of data mining is crucial for advancing our collective understanding of genetics and epigenetics, as it enables researchers to extract meaningful insights from vast and complex datasets. With the rapid growth of genomic data, the ability to analyze and interpret this information is more important than ever. Significant advances have already been made, such as the development of sophisticated algorithms that can identify genetic variants associated with diseases, and the integration of machine learning techniques to predict phenotypic outcomes.
Looking ahead, the potential for future advancements in data mining is immense. As technology continues to evolve, we may see the emergence of more refined predictive models that can personalize medicine, leading to tailored treatment strategies for individuals based on their unique genetic makeup. Additionally, the integration of multi-omics data—combining genomics, proteomics, and metabolomics—could provide a more holistic view of biological systems, paving the way for innovative solutions to complex health challenges. By continuing to advance our understanding in this area, we can unlock new possibilities for improving health outcomes and addressing pressing global issues.
We invite researchers to submit their work to this Collection, which will showcase research including but not limited to the following topics:
- Machine learning in genetics
- Genomic data integration
- Predictive modeling in cancer
- Non-coding RNA analysis
- Epigenetic data mining
- Big data in plant genetics
- Microbial genomics
- Data mining techniques in healthcare
All submissions in this collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the Editor-in-Chief. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief.
Publishing Model: Open Access
Deadline: Jul 10, 2025
Single-cell multi-omic analysis of cancer interactome
Cancer is a heterogeneous disease characterized by diverse cellular compositions and complex molecular regulatory networks. Recent advancements in single-cell technologies, such as single-cell and single-nucleus RNA and ATAC sequencing, have opened up new avenues for systems biologists to delve deeper into cancer interactomes. By integrating transcriptomic and epigenomic data at single-cell resolution, researchers now can uncover cell type-specific regulatory modalities, leading to a more precise understanding of cancer initiation, progression, and evolution. These tools can revolutionize cancer research by enabling the discovery of novel biomarkers and the development of personalized therapies.
This Collection invites submissions that develop innovative computational methods to integrate single-cell multi-omic (scRNA- and scATAC-seq) data or profile samples using both technologies to uncover novel insights into cancer. We prioritize studies that leverage existing atlas-level or landmark datasets or focus on identifying cell type-specific interactions through integrative analysis. Benchmark studies of prior multi-omic data integration algorithms, highlighting their strengths and limitations across diverse cancer types and single-cell data characteristics, are likewise preferred. Analysis guided or jointly analyzed with bulk sequencing profiles from the same cancer type is encouraged but not required. Submissions must leverage both scRNA-seq and scATAC-seq data to investigate cellular heterogeneity and regulatory mechanisms. Researchers are welcome to submit original research or review articles on topics that include, but are not limited to:
- Novel computational approaches for integrating scRNA-seq and scATAC-seq data
- Comparative analysis of existing integration methods
- Benchmarking integration methods on diverse cancer types and data characteristics
- Inferring cell type-specific regulatory networks
- Identifying cancer cell hierarchies and lineage relationships
- Characterizing tumor microenvironment and immune cell interactions
- Reverse-engineering cancer interactomes across regulatory modalities
- Understanding the interplay between transcription and chromatin accessibility in cancer
- Concurrent RNA and chromatin accessibility profiling of cancer
- Uncovering novel regulatory mechanisms underlying cancer initiation and progression
- Identifying potential therapeutic targets and biomarkers
- Predicting patient response to treatment and drug resistance
All submissions in this collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the Editor-in-Chief. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief.
Publishing Model: Open Access
Deadline: Oct 10, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in